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Abstract
Tuberculosis (TB) is one of the main infectious diseases worldwide and accounts for many deaths. It is caused by Myco-
bacterium tuberculosis usually affecting the lungs of patients. Early diagnosis and treatment are essential to control the TB 
epidemic. Interferon-gamma (IFN-γ) is a cytokine that plays a part in the body’s immune response when fighting infection. 
Current conventional antibody-based TB sensing techniques which are commonly used include enzyme-linked immuno-
sorbent assay (ELISA) and interferon-gamma release assays (IGRAs). However, these methods have major drawbacks, 
such as being time-consuming, low sensitivity, and inability to distinguish between the different stages of the TB disease. 
Several electrochemical biosensor systems have been reported for the detection of interferon-gamma with high sensitivity 
and selectivity. Microfluidic techniques coupled with multiplex analysis in regular format and as lab-on-chip platforms have 
also been reported for the detection of IFN-γ. This article is a review of the techniques for detection of interferon-gamma 
as a TB disease biomarker. The objective is to provide a concise assessment of the available IFN-γ detection techniques 
(including conventional assays, biosensors, microfluidics, and multiplex analysis) and their ability to distinguish the differ-
ent stages of the TB disease.
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Introduction
Tuberculosis (TB) is a lethal infectious disease caused by 
Mycobacterium tuberculosis, which affects the lungs and 
the respiratory organs of patients [1, 2]. It is a contagious 
airborne disease that is transmitted when infectious patients 
cough, spit, or sneeze [3]. It is among the deadliest diseases 
in the world, which caused approximately 1.6 million deaths 
in 2017, surpassing deaths due to human immunodeficiency 
virus/acquired immune deficiency syndrome (HIV/AIDS) in 
the same year [4]. Globally, the number of people infected 
with M. tuberculosis bacteria is estimated to be 1.7 billion, 
which is about 25% of the world’s population [5]. A person 
infected with M. tuberculosis could develop latent TB infec-
tion (LTBI), which is described as the lack of TB symptoms, 
yet having a 5–10% chance of developing active TB. This 
poses a significant problem as LTBI individuals are potential 
future active TB cases, especially in countries that have high 
HIV burden. The estimated annual rate of TB infection is 9 
million, out of which 1.5 million cases are fatal. Patients that 
are infected with HIV have a high risk of developing active 
TB, and HIV-TB co-infection is responsible for 20% of all 
TB-related deaths. Early diagnosis of active TB followed 
by treatment with rifampicin, isoniazid, and ethambutol and 
the identification and preventative treatment of latent TB 
infection are the most effective methods of controlling TB 
epidemic [6–8]. The Mantoux tuberculin skin test (TST) is 
one of the tests used to diagnose TB infection. The test is an 
intradermal injection of tuberculin purified protein deriva-
tive (PPD) and relies on the delayed hypersensitivity of the 
person’s cell-mediated immune response to the tuberculin 
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antigens. After the injection, the skin will produce a local-
ized induration in which the diameter is measured in mil-
limeters of the induration and elucidated using risk cutoffs 
[9]. The test has poor specificity due to the PPD which 
encompasses a complex mixture of a variety of mycobacte-
rial antigens that are not specific to M. tuberculosis with 
some even being expressed by the Bacille Calmette-Guerin 
(BCG) vaccine strains and nontuberculosis mycobacteria 
[10, 11]. For this reason, the TST is not an effective diag-
nostic technique, because of the cross-reactivity with non-
tuberculosis mycobacteria and the Bacille Calmette-Guerin 
(BCG) vaccine. In addition, the sensitivity of the TST test 
in patients that have compromised immune systems is poor. 
Also, the test only detects TB infection, but it is incapable of 
distinguishing active TB infection from LTBI [12, 13]. The 
polymerase chain reaction (PCR)-based technique, GeneX-
pert MTB/RIF test offers the real-time detection of the M. 
tuberculosis gene and the mutation of the rpoB gene that 
causes rifampicin resistance, consequently improving detec-
tion rates of Mtb. In this technique, the M. tuberculosis and 
rpoB gene sequence is amplified using PCR and is detected 
using a molecular beacon. The detection and processing of 
results are done nearly automatically within 2 h. The test 
has a disposable plastic cartridge with the necessary buffers 
and reagents required for processing [14, 15]. The disad-
vantages of this technique are that it is expensive, has a low 
sensitivity for re-infected patients, only detects pulmonary 
TB infection, and does not detect latent TB infection. A test 
that uses host biomarkers is a better diagnostic option, since 
it gives information on the pathological process and the host 
immune responses to active TB, pulmonary TB, and latent 
TB infection [16, 17]. A biomarker is a molecule that can be 
evaluated and measured to display a pathogenic biological 
process. They can be employed in the development of diag-
nostic devices and sensors for the detection of various dis-
eases such as cancer, HIV, SARS-CoV-2, and tuberculosis 
[18–22]. Biomarkers that are specific to a host or a pathogen 
can provide valuable prognostic information about a patient, 
with regard to predicting disease reactivation, cure, and vac-
cine-induced protection [23]. Interferon-gamma (IFN-γ) is 
among the host biomarkers of TB infection that have been 
used in TB diagnostics. It is a cytokine that is part of the 
interferon family that includes different groups of interferon, 
notable types I, II, and III. Interferon-gamma is type II and 
is pleiotropic in nature [24]. Interferon-gamma is produced 
by T cells, natural killer (NK) cells, and NKT cells, and its 
receptor is expressed on a variety of cell types. The produc-
tion of interferon-gamma is administered by the secretion of 
interleukin-12 (IL-12) and interleukin-18 (IL-18) cytokines. 
These cytokines aid in linking infection with the production 
of interferon-gamma in the innate immune response. Inter-
feron-gamma induces pro- and anti-inflammatory responses 
due to the binding of its receptors that initiates the Janus 
kinase (JAK)/signal transducer and activator of transcription 
(STAT) signaling pathway [25, 26]. It is a cytokine that plays 
a role in the body’s immune response when fighting myco-
bacterial infection; it does this by activating macrophages 
that kills the intracellular mycobacteria [27, 28]. For this 
reason, detection of interferon-gamma is important, and over 
the years, it has been detected using various techniques from 
immunoassays to optical and electrochemical-based tech-
niques. This article is a review of the advances in IFN-γ-
based TB diagnostics, including the advantages of biosensor 
techniques over the conventional techniques. Microfluidics 
and multiplex-based biosensor methods are also reviewed.
Conventional assay techniques
Interferon‑gamma release assay
Interferon-gamma release assay (IGRA) is an immune-
based blood test for M. tuberculosis infection. The princi-
ple of the assay is based upon the individuals’ T cell 
immune response when they are sensitized to tuberculosis-
specific antigens which makes them produce interferon-
gamma when they re-encounter mycobacterial antigens. If 
a substantial amount of interferon-gamma is produced, it 
would be presumed to be an indication of tuberculosis 
infection [29]. In this assay, the amount of interferon-
gamma which is released from CD4 and CD8 lymphocytes 
after stimulation with the tuberculosis antigens is quanti-
fied and detected [30]. The antigens used in the assay are 
culture filtrate protein 10 (CFP10) and early secretory 
antigenic target 6 (ESAT6). The specificity of this test is 
better than that of TST, and not affected by prior BCG 
vaccination [31]. The drawback of the IGRA test is that it 
has low sensitivity for active TB, especially in patients that 
have compromised immune systems. The IGRA test does 
not distinguish between active TB and latent TB infec-
tions, and thus, it is not recommended for the diagnosis of 
active TB disease [32]. There are three commercially 
available interferon-gamma release assays that have been 
developed to detect interferon-gamma in blood samples. 
It is the QuantiFERON-TB Gold In-Tube (QFT) assay 
(Cellestis, Australia), the QuantiFERON-TB Gold Plus 
(QFT-Plus) assay (Qiagen), and the T-SPOT-TB assay 
(Immunotec, Oxford). All three have been approved by the 
US Food and Drug Administration (FDA) and recom-
mended for use by the US Centers for Disease Control and 
Prevention (CDC). The QFT assay is a whole blood assay 
that uses enzyme-linked immunosorbent assay (ELISA) to 
measure the amount of interferon-gamma released in 
response to in vitro stimulation with tuberculosis antigens 
CFP-10, ESAT6, and TB7.7 in an in-tube format. The 
results are expressed as IFN-γ per millimeter [9, 33]. A 
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new generation of the QFT assay was introduced in 2015 
by Qiagen named the QuantiFERON-TB Gold Plus (QFT-
Plus) assay. This assay includes an additional antigen tube 
(TB2). TB1 includes antigens CFP-10 and ESAT6 for 
stimulation of CD4 + T cell response; the antigen TB7.7 
that is present in QFT assay has been removed. TB2 
includes antigens that were specifically designed to stimu-
late an immune response from both CD4 + and CD8 + T 
cells. This was intended to increase the assays’ sensitivity 
for latent TB infection (LTBI) detection [34, 35]. The 
T-SPOT-TB assay is an enzyme-linked immunosorbent 
spot (ELISPOT) assay that uses separated and counted 
peripheral blood mononuclear cells (PBMCs) that is stim-
ulated with TB-specific antigens ESAT6 and CFP-10; the 
cells respond to the antigens by producing interferon-
gamma. The results of the reaction are spots of where the 
interferon-gamma was released. The results are expressed 
as the number of interferon-γ-producing T cells (spot-
forming cells) [9]. Kim et al. [36] hypothesized that com-
bining IFN-γ release assay (IGRA) with the tumor necro-
sis factor-alpha (TNF-α) release assay could differentiate 
active TB from latent TB infections. Using the ELISPOT 
assay on peripheral mononuclear cells, the authors 
reported a higher sensitivity and specificity (89% and 93%) 
when the IGRA and TNF-α tests were combined, than for 
IGRA alone [20]. Although their results appeared to be 
useful for diagnosing active TB, they got indeterminate 
results from their negative controls and the number of 
patients involved in the study is not big enough for draw-
ing clinical conclusions. Santos et  al. [37] worked on 
determining and comparing the sensitivity of the IGRA 
and tuberculin skin test (TST) separately and as a com-
bined approach in active TB patients. The TST induration 
measurements was understood by making use of two cutoff 
points: ≥ 5 mm (TST-5 mm) and ≥ 10 mm (TST-10 mm). 
They achieved a higher sensitivity when the two tests were 
used as a combined approach (  > 90%). Their study had 
limitations; they could not approximate the specificity of 
the tests and they used active TB patients to measure the 
sensitivity of the tests; therefore, they obtained a different 
response to patients with LTBI. Garcia et al. [38] deter-
mined the sensitivity of the QFT-Plus assay in children 
and adolescents with tuberculosis disease in a setting that 
has a low TB burden. They did a cross-sectional analysis 
within the Spanish Pediatric TB research network. They 
found that the sensitivity of the assay was 82.9% and the 
sensitivity in children of < 5 years was also lower than that 
in older children (78.7% and 86.7%). In their study, the 
performance of this assay was not superior to prior genera-
tions of QFT assays that achieved a sensitivity of 83%. In 
the study, the added TB2 tube in the QFT-Gold Plus assay 
identified a small portion of added cases that did not 
already indicate a positive response in TB1 tube. The 
limitations in their study are that their study will not be 
relevant in high TB burden countries where malnutrition 
and HIV-infections are common, as opposed to Spain 
where their study was conducted. They were not able to 
get the specificity of the QFT-Plus assay and did not 
include other interferon-gamma release assays in the study 
to compare with. They concluded their study by stating 
that the QFT-Plus assay cannot be used as a conjunctive 
test for TB diagnosis in children and adolescents in low 
TB burden countries due to the assays’ performance not 
being better than that of previous-generation QuantiF-
ERON-TB Gold in-Tube (QFT-GIT) assay. In a study con-
ducted by Suzukawa et al. [39], they evaluated the levels 
of cytokine using the QFT-Gold Plus assay in active tuber-
culosis patients. They hoped to find cytokines that would 
be useful for diagnosing active TB by using the QFT-Gold 
Plus and comparing it with the QuantiFERON-TB Gold. 
From their study, they found that in terms of diagnosing 
active TB, the level of IP-10 was much higher than those 
of IFN-γ suggesting that it can be used as a possible bio-
marker substitute to IFN-γ in the QFT-Plus assay. The 
levels of the cytokines (IFN-γ, IL-1RA, IL-2, IP-10, 
MCP-1, and MCP-1β) were distinctively varied between 
the active TB patients and the healthy controls, showing 
these cytokines’ participation in the pathogenesis of TB. 
When comparing the QFT-Gold Plus assay with the QFT 
assay, no significant superiority was seen between the two 
regarding the measurement of the cytokines in the super-
natants, and the levels of cytokines in the new TB2 tube. 
The limitations in their study were the notable difference 
in the background of their patients between the study 
groups, due to how they recruited the healthy patients, and 
they did not thoroughly determine if their patients had any 
immunosuppression or comorbidities among them. In 
another study, Du et al. [40] detected latent tuberculosis 
infection and potential active tuberculosis incidence 
among Chinese college students that tested positive for 
ELISPOT and TST tests. They used the fusion protein 
(rESAT-6/CFP-10) ELISPOT assay and those that tested 
positive from the assay were monitored for 3 years to 
determine the occurrence of active TB. They achieved a 
positivity rate of 40.7% from TST-positive students using 
the ELISPOT assay with only a few students developing 
active TB despite having a positive test for TST/ELISPOT 
assay. They were not able to determine the sensitivity and 
specificity of the ELISPOT assay in their study and their 
results were not an accurate reflection of latent tuberculo-
sis infection prevalence due to this study being small scale. 
Furthermore, Sellami et  al. [41] performed a study to 
determine how in accordance the TST and IGRA are with 
each other in detecting latent tuberculosis infection before 
undergoing biologic therapy in patients diagnosed with 
inflammatory disease. They discovered that the two tests 
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were in poor agreement with each other with the sensitiv-
ity of the tests each being low, although the sensitivity of 
IGRA was higher. They concluded their study stating that 
because of the higher specificity, interferon-gamma release 
assay should be used to diagnose latent tuberculosis infec-
tion before biologic therapy in chronic immune inflamma-
tory disease patients.
As discussed above, these conventional techniques for 
detecting interferon-gamma are sensitive and specific; how-
ever, they do not offer real-time detection and they require 
centralized laboratories that are expensive and need skilled 
technical staff to operate. These are the main drawbacks of 
these conventional detection methods. Developing portable, 
real-time, and sensitive techniques to detect interferon-
gamma at an affordable cost is crucial. Due to the advances 
in the research area of biosensor, microfluidics, and multi-
plex techniques, the discussion in the following sections of 
this review will be suitable to accomplish the above-stated 
objectives.
Sensor detection techniques
The non-sensor techniques mentioned above for interferon-
gamma detection need skilled personnel and complicated 
instrumentation that are only available in laboratories. For 
this reason, there is a need to design a portable system that 
is sensitive and rapid and that offers real-time analysis. Over 
the years, the field of biosensors has advanced immensely 
and has proven to be useful in various research areas from 
disease diagnostics to food and agriculture industry. Biosen-
sors are analytical devices that contain a bioreceptor and 
transducer. The bioreceptor is a biological compound (anti-
bodies, enzymes, cells, nucleic acids, etc.) that attaches to a 
specific analyte. The transducer is a component that relays 
the biological response into a measurable signal [42, 43]. 
Biosensors have shown to have advantageous features over 
conventional detection techniques, such as having high sen-
sitivity and specificity and being able to detect a variety of 
complex samples. They are also easy to use, portable, and 
providing real-time detection, which is a promising diag-
nostic method [44].
Fluorescent aptasensor
Biosensors that have aptamers as their biorecognition ele-
ment are called aptasensors [45]. Aptamers are artificial 
single-stranded DNA or RNA molecules that change their 
conformation when binding to a target [46, 47]. They have 
become an alternative to antibodies over recent years due to 
their more favorable conditions such as high chemical and 
thermal stability, and their ease of modification, high speci-
ficity and affinity for any target, and good reproducibility 
[48, 49]. In fluorescent sensors, the biorecognition element 
or target molecule is labeled with a fluorescent tag and the 
fluorescent intensity reveals how strong the interaction 
between target and biorecognition molecule is [50]. Zhang 
et al. [51] developed a malachite green (MG)-bonded G 
quadruplex aptamer fluorescence biosensor to detect inter-
feron-gamma (IFN-γ) with high sensitivity and specificity. 
Nicking enzyme-assisted signal amplification and molecu-
lar beacon (MB) track-mediated DNA walker were used as 
an integrated approach when developing the biosensor. In 
Fig. 1, the schematic diagram of the biosensor fabrication 
is revealed. They achieved a limit of detection of 7.65 fM 
in buffer with a linear range of 0 fM–20 pM and a recov-
ery range of 95.29–118.08% in real sample. They were able 
to accomplish a high sensitivity and specificity to target. 
Although they were able to achieve high sensitivity and 
low detection limit, their method is long and includes a lot 
of steps. Another fluorescent aptasensor was developed by 
Taghdisi et al. [52]; they used an oligonucleotide with a 
hairpin structure that contained biotinylated aptamer and 
poly thymine sequence. The sensor was also based on sin-
gle-stranded DNA binding protein, streptavidin-coated silica 
nanoparticles, and fluorescent copper nanoparticles. When 
no target was added, the aptamer kept its structure, and with 
ascorbic acid introduction, the copper ions used the stem of 
the hairpin structure as a template to form fluorescent copper 
nanoparticles which gave off a high fluorescence intensity. 
When the target was added, the aptamer lost its structure and 
a weak fluorescence intensity was measured because less flu-
orescent copper nanoparticles was formed due to the loss of 
the aptamer stem region. They achieved a detection limit of 
1 pg/mL, a linear range of 10 pg/mL–4 ng/mL, and a recov-
ery range of 92.52–98.32% in spiked human serum samples. 
In Dhenadhayalon et al.’s study [53], they developed a fluo-
rescent aptasensor that utilized two-dimensional nanosheets 
 ReS2 and  TiS2 as their platform. Fluorescence resonance 
energy transfer (FRET) was observed in their system, in 
which the fluorescence was quenched and then recovered 
because of the interaction of the dye-labeled aptamer with 
the nanosheets and target. The detection limit of interferon-
gamma obtained by them was 57.6 pM and 82.7 pM with a 
linear range of 0–400 pM and 0–300 pM for  ReS2 and  TiS2, 
respectively. In Wen et al.’s study [54], they too developed a 
fluorescent sensor but theirs was based on DNA click polym-
erization. They designed a new fluorescent sandwich that 
comprised of aptamer/protein/aptamer which proved to be 
sensitive, selective, and stable during detection, specifically 
when the sandwich was immobilized with magnetic  Fe3O4 
nanoparticles. The fluorescent sensor detected interferon-
gamma to as low as 0.175 fM and obtained a broad linear 
range of 0.01 pM to 10 nM; however, when detected in fetal 
bovine serum, they attained a detection limit of 1.63 fM. 
In another study done by the same group, Wen et al. [55] 
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fabricated the sensor utilizing sequential dual atom transfer 
radical polymerization to amplify their signal. Their first 
aptamer was immobilized with magnetic  Fe3O4 nanoparti-
cles while the second aptamer was modified with initiators 
of dual atom transfer radical polymerization. Polymer fluo-
rescein-o-acrylate (FA) grew directly from their nanoparticle 
surface forming an aptamer/protein/aptamer/polymer super 
sandwich sensor. The sensor obtained a wide linear range of 
0.002 fM–50 nM with detection limit of 0.178 fM in phos-
phate buffer and 1.54 fM in human serum.
Electrochemical aptasensor
Electrochemical sensors are sensing devices that couple a 
biological recognition element to an electrode transducer; 
the transducer then converts the biological recognition event 
into an electrical signal [56]. In a study conducted by Xu 
et al. [57], an electrochemical aptasensor was designed that 
was centered around an aptamer hairpin structure; their hair-
pin structure was a diblock dual allosteric aptamer. When 
the target was added, the hairpin structure opened caus-
ing hybridization and forming magnesium ion-dependent 
DNAzymes. The interferon-gamma binding sequence was 
removed in the presence of magnesium ions causing the 
allosteric aptamer switching from inactive to active hairpin. 
Streptavidin-inorganic hybrid nanoflowers with graphene 
composites (SFG) were prepared and utilized as the plat-
form to the sensor. The binding of the SFG with aptamer 
conjugated gold nanoparticles caused a high readout signal. 
A detection limit of 19 fg/mL and linear range of 0.1 pg/
mL–500 ng/mL were attained. Abnous et al. [58] developed 
an electrochemical aptasensor for the rapid, selective, and 
sensitive determination of interferon-gamma. The aptasen-
sor was focused on a triple-helix molecular switch (THMS) 
system, aptamer, and a methylene blue redox probe. When 
no target was added, the THMS was able to hold its structure 
on the electrode surface, allowing for the binding with meth-
ylene blue which ensued in a high electrochemical signal 
readout. The addition of target, interferon-gamma, resulted 
in THMS losing its structure ensuing in the aptamer/IFN-γ 
compound leaving the electrode surface. This caused an 
insufficient amount of methylene blue to bind to the sig-
nal probe on the electrode surface, producing a weak sig-
nal readout. They obtained a detection limit of 3 pg/mL 
and linear range of 10–1500 pg/mL. They also detected 
interferon-gamma in spiked serum samples and were able 
to obtain a recovery range from 91.3 to 102.8%. Although 
they achieved good results, they had difficulty in designing 
Fig. 1  Schematic diagram 
of the fluorescent aptasensor 
fabrication for IFN-γ detection. 
Copyright 2018 Elsevier [51]
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the THMS system for the aptamer to identify its target effi-
ciently. In another study, Li et al. [59] developed a label-
free impedance aptasensor that was based on target-induced 
exonuclease inhibition. The electron transfer resistance (Rct) 
increased when interferon-gamma was added, because of 
the double exonuclease reaction taking place. The sche-
matic diagram of the fabrication of the aptasensor is dis-
played in Fig. 2. The aptasensor attained a detection limit 
of 0.7 pM, a linear range of 1 pM–50 nM, and a recovery 
range of 91.83–101.9% in serum samples. Their sensor was 
found to be low in cost, sensitive, selective, and easy to 
operate and achieved good reproducibility. In Ding et al.’s 
study [60], they fabricated an electrochemical aptasensor 
that consisted of a ternary surface monolayer. The RNA 
aptamer was immobilized onto a gold interdigited electron 
array along with 1,6-hexanedithiol (HDT) and 6-mercapto-
1-hexanolphosphate (MCH). They used a ternary surface 
monolayer to inhibit nonspecific adsorption of nontarget, 
improve selectivity, and enable effective hybridization with 
the target. They detected interferon-gamma in fetal bovine 
serum and obtained a detection limit of 11.56 pM with a lin-
ear range of 22.22 pM–0.11 nM. In another study, Liu et al. 
[61] developed a gold-centered vertical silicon nanowire 
aptasensor for the sensitive detection of interferon-gamma. 
The nanowires were used as working electrodes and were 
functionalized with methylene blue-labeled aptamer. They 
compared the nanowire electrode to normal flat electrodes 
and found the nanowire electrode to be more sensitive 
with a faster response time. The linear range achieved by 
the nanowire aptasensor and flat electrode aptasensor was 
0.2–100 ng/mL and 1–280 ng/mL with a detection limit of 
0.14 ng/mL and 0.8 ng/mL, respectively. Furthermore, Jin 
et al. [48] fabricated an electrochemical label-free aptasensor 
that changed conformation from hairpin to linear when bind-
ing with the target. They prepared a composite composed 
of gold nanoparticles, poly(amidoamine) dendrimer, and 
molybdenum disulfide nanosheets (AuNPs-PAMAM/MoS2) 
and used it as a platform for their aptasensor. Methylene 
blue was used as a redox probe and was absorbed onto the 
aptamer surface, causing an increase in electrochemical sig-
nal. The signal of methylene blue steadily increased as more 
interferon-gamma was added.
They achieved a linear range of 0.01–1000  pg/mL 
with a detection limit of 2  fg/mL and a recovery range 
of 95.2–105% in human serum sample. Lastly, Cao et al. 
[62] developed a reusable graphene oxide-based aptasen-
sor device to detect interferon-gamma in vivo. The aptamer 
was labeled with ruthenium ion complex redox probe, 
Ru(NH3)63+, and it was released when the target was added, 
causing an increase in current which was measured. They 
achieved a linear range of 1.3–210 pg/mL and a detection 
limit of 1.3 pg/mL. For in vivo interferon-gamma detection, 
the device was implanted into the tissue of enteritis mice and 
measured for a long period of time. They achieved promis-
ing results for in vivo detection; however, the challenges 
associated with this method are the background drifting, 
interferences in complex sample matrix, and the possibility 
of fouling.
Electrochemical Immunosensor
When the biorecognition element in a biosensor is an anti-
body, it is termed an immunosensor. Immunosensors take 
advantage of the high affinity of antibodies to antigens for 
determination of specific analytes using an appropriate sig-
nal transducer [63]. Sanchez-Tirado et al. [64] designed an 
electrochemical immunosensor for interferon-gamma detec-
tion in saliva. The biosensor was centered on a sandwich-
type immunoassay consisting of a capture anti-IFN-γ anti-
body immobilized onto the electrode surface by diazonium 
salt grafting of p-aminobenzoic acid. Their detector anti-
body was labeled with biotin and conjugated with strepta-
vidin–horseradish peroxidase. The response was measured 
amperometrically when adding  H2O2 with hydroquinone 
being used as a redox couple. They achieved a detection 
limit of 1.6 pg/mL and linear range of 2.5–2000 pg/mL. 
Fig. 2  Schematic diagram 
of fabricated electrochemi-
cal impedance aptasensor for 
interferon-gamma determina-
tion. Copyright 2019 Elsevier 
[59]
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Moreover, Ruecha et al. [65] fabricated a label-free paper-
based impedance immunosensor. They modified the paper-
based electrode with polyaniline-graphene and immobilized 
human IFN-γ antibody onto it. Electrochemical impedance 
was used to detect interferon-gamma in human serum with 
high specificity and with the method proving to be sensitive, 
simple, rapid, and low in cost. A detection limit of 3.4 pg/
mL, linear range of 5–1000 pg/mL, and recovery range 
of 101–104% in human serum were realized. Meanwhile, 
Zhang et al. [66] also developed an electrochemical sand-
wich-type immunosensor. They designed disposable indium 
tin oxide electrode and used it to fabricate their immunosen-
sor. On the surface of the electrode, they used a compos-
ite comprised of poly(diallyldimethylammonium chloride) 
(PDDA) and gold nanoparticles to produce an effective 
biointerface; capture antibody that was labeled with horse-
radish peroxidase (HRP) and conjugated with gold nano-
particles was used as a signal tag. Hydrogen peroxide was 
added to aid in HRP’s oxidation of hydroquinone, inducing 
a reduction current. This current was an indication of the 
amount of immobilized HRP on the electrode surface and 
was directly correlated to interferon-gamma concentration. 
Their immunosensor had a detection limit of 0.048 pg/mL 
with a wide linear range of 0.1–1 ×  104 pg/mL. Furthermore, 
Parate et al. [67] designed an immunosensor for determi-
nation of cytokines, interferon-gamma and interleukin-10 
(IL-10). The immunosensor was based on aerosol-jet printed 
graphene and they printed the graphene interdigited elec-
trode using nitrocellulose ink on flexible polyimide film. 
For the IFN-γ and IL-10 antibodies to immobilize onto the 
graphene surface, the electrodes had to undergo  CO2 anneal-
ing to produce carboxyl groups on the surface. Their immu-
nosensor had a broad linear range: 0.1–5 ng/mL for IFN-γ 
and 0.1–2 ng/mL for IL-10. A detection limit of 25 pg/mL 
for interferon-gamma and 46 pg/mL for interleukin-10 was 
achieved with high selectivity.
Other sensor systems
There are several other sensor systems that detect inter-
feron-gamma that does not fall under the above cat-
egories; some are less common than others. Bao et al. 
[68] designed an electrochemical biosensor for inter-
feron-gamma detection based on several amplification 
approaches. Gold nanoclusters-graphene zeolitic imi-
dazolate framework-8 (AuNC-GR@ZIF-8) was used as 
their platform onto which an improved layered branch 
hybridization chain reaction took place and consisted of 
a cascade-like assemblage of four DNA hairpins. Two 
of the hairpins underwent hybridized chain reaction to 
form a long DNA double helix while the other two hair-
pins assisted in the growth of DNA nanostructures. When 
they added the target, dendritic DNA nanostructures 
were formed along with several in situ formed hemin/G 
quadruplex DNAzyme. An amplified signal output was 
obtained when the DNAzyme caused the catalyzed reduc-
tion of  H2O2 and thionine playing the role of electron 
mediator. The electrochemical signal increased when the 
concentration of interferon-gamma increased due to the 
increase of target, enabling the increasing formation of 
DNA nanostructures that improved the signal. The bio-
sensor obtained a detection limit of 0.6 fM and linear con-
centration range of 1 fM–50 pM with a recovery range of 
92.35–102.9% in human serum. In another study, Morales 
et al. [69] developed a DNA photoacoustic nanosensor 
for interferon-gamma detection. Photoacoustic sensors are 
based on the photoacoustic effect, an event that converts 
optical energy to acoustic waves providing functional and 
structural information. Their sensor was based on a phth-
alocyanine dye that increases the photoacoustic signal by 
22.5% when the dyes are stacked using IFN-γ receptor 
mediators. When interferon-gamma binds to the recep-
tors, it caused a conformational change in the DNA that 
induces dye stacking, which resulted in an increase in 
photoacoustic signal by 55% in the presence of 10 μM 
interferon-gamma. Surface plasmon resonance was used 
to determine the sensors’ dynamic range, reversibility, 
and responsiveness to interferon-gamma. They obtained 
affinities of KD1 2.8 μg/mL and KD2 5.3 μg/mL with a 
dynamic range of 0.01–2 ng/mL. Another type of sensor 
that is used, although rarely, is liquid crystal aptasen-
sor. Liquid crystals are molecules that have fluidity, 
optical anisotropy, and long-range orientational order 
that depends on the physical and chemical changes of 
the adjacent interface [70]. Liquid crystal sensing sys-
tems do not require labeling or complicated instrumenta-
tion [71]. Kim et al. [72] designed a liquid crystal-based 
aptasensor for detecting interferon-gamma. The sensor 
was based on the change in orientation of the liquid crys-
tal when interferon-gamma bound to the surface of the 
immobilized aptamer. The transformation in the align-
ment of the liquid crystals was observed by the change in 
the optical image. When a polarized light microscope was 
used, a detection limit of 17 pg/mL was obtained. They 
used their biosensor to see if it could detect latent TB in 
blood samples. The blood samples were stimulated with 
ESAT-6, a TB antigen followed by aptamer incubation 
on the immobilized surface. Their sensor was successful 
in detecting latent TB with good sensitivity. Although 
they achieved promising results, the number of blood 
samples measured was wanting. Lastly, Pohanka et al. 
[73] developed a quartz crystal microbalance (QCM) 
biosensor to detect interferon-gamma. The biosensor was 
developed for the purpose of being able to compete with 
the traditional method of detecting IFN-γ and for use in 
on-field application. Monoclonal rat antibodies against 
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human interferon-gamma were immobilized onto the gold 
electrode surface of the quartz crystal microbalance by 
self-assembled monolayer. Gold nanoparticles were then 
modified with monoclonal mouse antibody against human 
interferon-gamma. A sandwich-type assay was formed 
between the quartz crystal microbalance, IFN-γ antibod-
ies, and gold nanoparticles. The biosensor achieved a 
detection limit of 5.7 pg/mL, and when compared with 
ELISA, it achieved a better limit of detection; however, 
when tested on real plasma samples, they achieved similar 
results. The biosensor had good long-term stability, is 
simple, cost-effective, and suitable for mass production 
and does not need any technical laboratory staff to use 
it. It was concluded that the biosensor can compete with 
ELISA; however, too little real samples were tested to 
make this statement. In Table 1, a summary of the various 
biosensors for interferon-gamma detection is displayed.
Microfluidic‑based detection techniques
In recent years, microfluidic devices have emerged as a 
possible diagnostic tool to be used in countries with low 
resources. Microfluidic devices are chip-based sensing tech-
niques that make use of small sample volume to provide 
real-time, point of care diagnosis of infectious disease. A 
broad range of clinical samples can be analyzed using micro-
fluidics such as urine, blood, or saliva [74]. The microflu-
idics can be fabricated on various surfaces such as glass, 
polydimethylsiloxane (PDMS), silicon, and even paper [75]. 
They offer the advantage of being low in cost and compact 
and can be mass produced [76]. Yang et al. [77] fabricated 
a sensitive microchip electrophoresis chemiluminescence 
(MCE-CL) assay platform that was focused on cascade sig-
nal amplification. They used a double T-type glass micro-
fluidic chip that has a broad Y-type chemiluminescence 
Table 1  Various types of biosensors for interferon-gamma detection















Fluorescent aptasensor Fe3O4-aptamer 1/IFN-γ/aptamer 2/dsDNA 0.169–169 ×  105 2.95 ×  10−3 [54]
Fluorescent aptasensor Fe3O4-aptamer 1/IFN-γ/aptamer 2-PBiB-
pBIEM
3.38 ×  10−5–8.44 ×  105 3 ×  10−3 [55]
Electrochemical aptasensor SFG/GCE/A-DDAH and AuNPs 0.1–5 ×  105 0.019 [57]
Electrochemical aptasensor SPGE/STP/aptamer/MB 10–1500 3 [58]
Electrochemical aptasensor GE/aptamer/IFN-γ/Exo I and Exo III 16.9–8.44 ×  105 11.8 [59]
Electrochemical aptasensor Au IDE/ACP/HDT-MCH 375–1860 195 [60]
Electrochemical aptasensor Au-SiNWs/MB-aptamer/MCH 200–1 ×  105 140 [61]
Electrochemical aptasensor Aptamer-AuNPs-PAMAM/MoS2/GCE 0.01–1000 0.002 [48]




Paper-based electrochemical immunosensor BSA/hIFN-γ mAb/PANI-G electrode 5–1000 3.5 [65]
Electrochemical immunosensor HRP-Ab2-AuNPs/IFN-γ/BSA/Ab1/AuNP/
PDDA/ITO
0.1–1 ×  104 0.048 [66]
Electrochemical immunosensor AJP graphene IDE-anti-IFN-γ-BSA-Tween-
20-fish gelatin
100–5000 25 [67]
Electrochemical DNAzyme biosensor T-DNA/MCH/CP/AuNCs-Gr@ZIF-8/GCE 0.0169–844 0.01 [68]
DNA photoacoustic nanosensor Streptavidin-coated SPR chip-IFN-γR2-IFN-
γR1-IFN-γ
10–2000 KD1 2.8 ×  106
KD2 5.3 ×  106
[69]
Liquid crystal aptasensor APTES/DMOAP-treated glass-aptamer-
ethanolamine
- 17 [72]
Quartz crystal microbalance immunosensor AuE/cysteamine-glutaraldehyde-anti-IFN-γ-
gelatin
- 5.7 [73]
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detection cell. The cascade signal amplification reaction 
was activated when the aptamer bound to interferon-gamma. 
DNA labeled with HRP was used as the signal probe for 
chemiluminescence detection, combined with exonuclease 
signal amplification strategy which allowed for sensitive and 
selective detection of interferon-gamma in human plasma. 
The detection limit achieved was 1.6 fM with a linear range 
of 8 ×  10−15–1 ×  10−8 M. In another study, Liu et al. [78] 
fabricated a microfluidic device that detects interferon-
gamma continuously in blood serum and cell culture. Their 
microfluidic device included a bottom and top layer with 
both being PDMS based. It had an inlet, sample channel, 
sensor loading, and outlet zone. The device was centered 
on the integrated conformational change of aptamers. Their 
aptamer hairpin structure was labeled with ferrocene and 
immobilized onto magnetic nanobeads. They formed their 
sensing platform by using a magnetic field to confine the 
aptamer-modified magnetic nanobeads onto the microfluidic 
chip. When the aptamer bound to interferon-gamma, it lost 
its structure causing a decrease in electrochemical signal due 
to the ferrocene molecules moving away from the sensing 
platform. A diagram of the microfluidic chip and fabrication 
of the sensing platform is displayed in Fig. 3. The difference 
in reduction current was directly correlated to interferon-
gamma concentration and a detection limit of 6 pg/mL, lin-
ear range of 10–500 pg/mL, and recovery range of 98–102% 
in human serum samples were obtained. Furthermore, Evans 
et al. [79] designed a lab-on printed circuit board sensor 
platform that contained an in-line assay cells and PMMA 
microfluidic electrochemical cells. Their system was made 
to cater for ELISA and was performed under controlled flow. 
They performed amperometric detection using a multi-chan-
nel instrument platform. They obtained a detection limit of 
40 pg/mL along with a linear range between 15 and 2000 pg/
mL and recovery range of 93–97% in spiked plasma sam-
ples. The performance of the microfluidic biosensor system 
was comparable to commercial systems in addition to being 
a microfluidic assay that its whole diagnostic analysis takes 
an approximate 8 min.
In another study, Baganizi et al. [80] fabricated a PDMS-
based microfluidic device combined with an antibody micro-
array chip to determine T cell-secreted interferon-gamma 
and interleukin-2 (IL-2) cytokines. The T cell was captured 
on the microarray surface after it was injected onto the bio-
chip through the fluidic system and the cytokines secreted 
during this process were detected when they interacted with 
their specific antibodies that were grafted near the surround-
ing area of secreted cells. The secretion of the cytokines 
was analyzed after a 24-h incubation period using immu-
nofluorescence and continuous surface plasmon resonance 
imaging. They detected interferon-gamma and interleukin-2 
down to nanomolar concentrations, 0.15 nM for IFN-γ and 
0.1 nM for IL-2 in bulk medium. In Table 2, a summary of 
the microfluidic techniques for interferon-gamma detection 
is displayed.
Fig. 3  Schematic diagram of microfluidic chip and fabrication of the sensing platform. Copyright 2019 Creative Commons [78]





Limit of detection (pg/mL) References
Glass 0.027 0.135–1.69 ×  105 [74]
PDMS 10–500 6 [75]
PMMA 15–2000 40 [76]
PDMS - IFN-γ: 2530
IL-2: 1690
[77]
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Multiplex detection of TB biomarkers
Multiplex assay detection is a technique that allows meas-
urement of multiple analytes simultaneously [81]. It has 
garnered a lot of attention in recent years due to its sim-
plicity, rapidness, requirement of smaller sample volumes, 
and less consumption of reagents when compared to multi-
ple single target techniques [82]. Wang et al. [83] theorized 
that using multiplex biomarker assays instead of single 
cytokine assays to diagnose active TB could enhance the 
diagnostic performance for TB detection. They analyzed 
multiple biomarkers with a microbead-based multiplex 
assay, and among them, five chemokines/cytokines were 
able to distinguish between active pulmonary TB patients 
and healthy controls and they were IFN-γ, interferon-
gamma-inducible protein-10 (IP-10), interferon-gamma-
induced monokine (MIG), IL-2, and tumor necrosis fac-
tor-alpha (TNF-α). They discovered that the multiplex 
detection of IFN-γ, IP-10, and IL-2 achieved a much better 
diagnostic performance for TB than when detected indi-
vidually. In another study, Won et al. [84] studied differ-
ent biomarkers that could distinguish between active and 
latent TB disease. The biomarkers were measured using 
a Luminex assay on the supernatants of QuantiFERON 
tube assay. They found that when measuring a combina-
tion of cytokines, they were able to distinguish between 
different states of TB. The combination of biomarkers 
that performed the best was IL-5, TNF-α, IL-10, vascular 
endothelial growth factor (VEGF), and a ratio of IL-2/
IFN-γ. They accurately predicted 93.3% of latent TB and 
95.5% of active TB cases. The biomarker that stood out 
in their study was VEGF because it was able to differen-
tiate between TB states irrespective of stimulation. Yao 
et al. [85] analyzed multiple chemokines and cytokines 
in unstimulated and stimulated samples and whether they 
could be used as potential biomarkers that can be cor-
related with latent TB and active TB. The cytokines and 
chemokines were measured using a multiplex assay based 
on microbead. In their study, they found that the possible 
biomarkers that can discern between latent and active TB 
were IL-8, VEGF, and monocyte chemotactic protein-3 
(MCP-3) for stimulated samples and IL-8, IP-10, mac-
rophage inflammatory protein-1 alpha (MIP-1α), and 
interleukin-2 receptor alpha (IL-2Rα) for unstimulated 
samples. In Zhou et al.’s [86] study, they fabricated an 
electrochemiluminescence (ECL) immunosensor to detect 
IFN-γ, IL-2, and TNF-α simultaneously. The detection 
was done on an ITO electrode surface that was spatially 
spaced to negate interference amongst the ECL probes and 
employed potential resolved ECL nanoprobes to amplify 
the electrochemiluminescence signal. The schematic 
diagram of their immunosensor fabrication process is 
displayed in Fig. 4. Their immunosensor achieved a detec-
tion limit of 1.6 pg/mL and linear range of 1.6–200 pg/mL 
for all three biomarkers. They also detected the three latent 
TB biomarkers in human serum and obtained a recovery 
range of 104.2–108.4, 104.8–109.6, and 98.8–105.6% for 
IFN-γ, TNF-α, and IL-2, respectively. In another study, 
Shen et al. [87] developed an electrochemical aptasen-
sor based on aptamer beacons to detect three cytokines 
(VEGF, IFN-γ, and TNF-α) simultaneously and in real 
time. The biotinylated aptamers were labeled with dif-
ferent redox labels for each cytokine and immobilized 
onto a gold electrode modified with graphene oxide and 
streptavidin. The conformation of the aptamers changed 
in the presence of the cytokines, resulting in the redox 
labels causing a change in electrochemical signal that cor-
responded to the cytokines’ concentration. They achieved 
a limit of detection of 5 pg/mL in buffer for each cytokine 
and a linear range of 5–300 pg/mL for VEGF, 5–300 pg/
mL for IFN-γ, and 5–200 pg/mL for TNF-α.
Chen et al. [88] detected six cytokines (IL-2, IL-4, IL-6, 
IL-10, TNF-α, and IFN-γ) in complex serum matrix. For 
the analysis, they developed a multiarray localized surface 
plasmon resonance (LSPR) microfluidic optical biosen-
sor device for parallel detection of the cytokines in micro 
volume serum sample. They achieved a wide linear range 
of 10–10,000 pg/mL for each of the cytokines. The limit 
of detection for each cytokine biomarker was 11.43, 6.46, 
20.56, 4.60, 11.29, and 10.97 pg/mL for TNF-α, IFN-γ, 
IL-2, IL-4, IL-6, and IL-10, respectively. In Table 3, a sum-
mary of the microfluidic techniques for interferon-gamma 
detection is displayed.
Conclusion
Tuberculosis is amongst the deadliest diseases in the world 
and is a massive global health issue. The early detection and 
diagnosis of this disease are therefore imperative. Over the 
years, there has been many methods used to detect tubercu-
losis such as the Mantoux tuberculin skin test and GeneX-
pert, the PCR-based technique. In this review, we focused on 
the detection of interferon-gamma, a tuberculosis cytokine 
biomarker. Interferon-gamma is conventionally detected 
using the interferon-gamma release assays. They are how-
ever labour intensive, do not distinguish between latent and 
active tuberculosis, and are not sensitive enough especially 
in immune-compromised patients. With the introduction of 
the detection of interferon-gamma using biosensing plat-
forms, the sensitivity, specificity, and overall simplicity 
increased. When compared to conventional techniques, it 
has exceeded them with regard to accuracy, cost, and time. 
Despite all the advantages of biosensors, there is still a long 
way to go to integrate biosensors into real-world clinical 
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applications given that there is such a limited amount used 
with the glucose sensor being the exception. The introduc-
tion of microfluidics and multiplex detection to the sensing 
systems made diagnosis much easier and can now be used 
as a lab-on chip platform minimizing the need for labora-
tory equipment. However, translation of microfluidics into 
the commercial market has yet to make a big impact due to 
some challenges that still need to be addressed such as raw 
Fig. 4  Schematic diagram of the 
fabrication of multiplex immu-
nosensor for determination of 
latent TB biomarkers. Copy-
right 2017 American Chemical 
Society [86]
Table 3  Multiplex detection of tuberculosis biomarkers
Biomarkers measured Technique used Detection limit (pg/mL) Linear range (pg/mL) References






IL-5, TNF-α, IL-10, VEGF, and IL-2/IFN-γ Multiplex assay - - [81]
IL-8, VEGF, MCP-3, IP-10, MIP-1α, and IL-2Rα Multiplex assay - - [82]
IFN-γ, IL-2, and TNF-α Immunosensor 1.6 1.6–200 [83]
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sample analysis and the cost of mass-producing microfluid-
ics. There is also not adequate research done on multiplexed 
detection techniques on biosensor platforms and there are no 
dignified techniques or point of care device that can distin-
guish the different stages of tuberculosis. If scientists want to 
control the tuberculosis burden globally, these are the areas 
that need increased focus along with developing platforms 
that are inexpensive and reusable and that can be used in 
developing countries.
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